[{"orgOrder":0,"company":"Marksans Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Marksans Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Marksans Pharma \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Marksans Pharma \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Strides Pharma Science \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Inapplicable"},{"orgOrder":0,"company":"Harvard Medical School (HMS and HSDM)","sponsor":"Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harvard Medical School (HMS and HSDM)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Medical School (HMS and HSDM) \/ Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men","highestDevelopmentStatusID":"10","companyTruncated":"Harvard Medical School (HMS and HSDM) \/ Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men"},{"orgOrder":0,"company":"Harvard Medical School (HMS and HSDM)","sponsor":"National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Harvard Medical School (HMS and HSDM)","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harvard Medical School (HMS and HSDM) \/ National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal","highestDevelopmentStatusID":"10","companyTruncated":"Harvard Medical School (HMS and HSDM) \/ National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"}]

Find Clinical Drug Pipeline Developments & Deals for Prizma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Fluoxetine hydrochloride, is an antidepressant of the SSRIs class. It is used for the treatment of major depressive disorder, obsessive–compulsive disorder, bulimia nervosa, etc.

                          Product Name : Prozac-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          September 18, 2024

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Strides Pharma Science

                          02

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Fluoxetine hydrochloride (Prozac) is an SSRI antidepressant used for major depressive disorder, OCD, bulimia, and panic disorder.

                          Product Name : Prozac-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 04, 2024

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Strides Pharma Science

                          03

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 20, 2010

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          04

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 20, 2010

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          05

                          Harvard Medical School (HMS and HSDM)

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Harvard Medical School (HMS and HSDM)

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase III

                          Sponsor : National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 01, 2023

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : National Institute of Mental Health | Harvard School of Public Health (HSPH) | Massachusetts General Hospital | Centre for Addiction and Mental Health | Brigham and Women's Hospital | Vanderbilt University | All India Institute of Medical Sciences, Bhopal

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase II

                          Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 17, 2023

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Harvard Medical School (HMS and HSDM)

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Harvard Medical School (HMS and HSDM)

                          Country arrow
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase III

                          Sponsor : Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 13, 2023

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Sangath | All India Institute of Medical Sciences, Bhopal | Vanderbilt University | Brigham and Women's Hospital | Centre for Addiction and Mental Health | Massachusetts General Hospital | Harvard School of Public Health (HSPH) | National Institute of Men

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It is indicated for both acute and maintenance treatment of MDD, OCD, and bulimia nervosa; however, it is only indicated for acute treatment of ...

                          Product Name : Fluoxetine Hydrochloride-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 23, 2023

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Fluoxetine is used to treat depression, panic attacks, obsessive compulsive disorder, a certain eating disorder (bulimia), and a severe form of premenstrual syndrome (premenstrual dysphoric disorder).

                          Product Name : Fluoxetine-Generic

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 28, 2022

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Study Phase : Phase II

                          Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 16, 2022

                          Lead Product(s) : Fluoxetine Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase II

                          Sponsor : U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank